zpharmacology Flashcards
Enzyme kinetics:
- Michaelis-Menten kinetics
- Lineweaver-Burk plot
- Enzyme inhibition
- Michaelis-Menten kinetics
- Km is inversely related to the affinity of the enzyme for its substrate.
- Vmax is directly proportional to the enzyme concentration
- most enzyme reactions follow a hyperbole curve (follow Michaelis-Menten kinetics). However, enzymatic rnxs that follow cooperative kinetics (hemoglobin) have sigmoid curve. - Lineweaver-Burk plot
- inc y-intercept, dec Vmax
- the further to the right the x-intercept, the greater the Km, and lower the affinity - Enzyme inhibition
- competitive inhbitors cross each other competitively, whereas noncompetitive inhibitors do not
Pharmacokinetics:
- Bioavailability (F)
- Volume of distribution (Vd)
- Bioavailability (F)
- fraction of administered drug that reaches systemic circulation unchanged
- for an IV dose F=100%
- orally, F typically <100% to incomplete absorption and first pass metabolism - Volume of distribution (Vd)
- theoretical fluid volume required to maintain the total absorbed drug amount at the plasma concentration
- Vd of plasma protein-bound drugs can be altered by liver and kidney disease (dec protein binding, inc Vd)
- Vd=amount of drug in body/plasma drug concentration
Volume of distribution (Vd): distribution, drug types
- low (4-8L)
- Medium
- High
Vd, distribution, drug types
- Low (4-8L)bloodlarge/charged molecules; plasma protein bound
- mediumECFsmall hydrophilic molecules
- Highall tissuessmall lipophilic molecules, especially if bound to tissue protein
Pharmacokinetics:
- Half-life (t1/2)
- Clearance (CL)
1.Half-life (t1/2)
-The time required to change the amount of drug in body by ½ during elimination (or constant infusion).
-property of first-order elimination.
-A drug infused at a constant rate takes 4-5 half lives to reach steady state
T1/2=0.7 x Vd/CL
2.Clearance (CL)
-relates the rate of elimination to the plasma concentration
-clearance may be impaired with defects in cardiac, hepatic, or renal function
CL=rate of elimination of drug/plasma drug concentration/plasma drug concentration=Vd x Ke (elimination constant)
Dosage calculations
-loading dose=Cp x Vd/F
-maintenance dose=Cp x CL/F
Cp=target plasma concentration
-in renal or liver dz, maintenance does dec and loading dose is unchanged
-time to steady state depends primarily on t1/2 and is independent of dosing frequency or size
Elimination of drugs:
- zero-order elimination
- first-order elimination
- zero-order elimination
- rate elimination is constant regardless of Cp (ie. Constant amount of drug elimination per unit time)
- Cp dec linearly with time
- examples of drugs: Phenytoin, Ethanol, Aspirin (at high or toxic concentration)
- capacity-limited elimination
* **PEA (a pea is round, shaped all the 0 like in zero-order - first-order elimination
- rate of elimination is directly proportional to the drug concentration (ie. Constant fraction of drug eliminated per unit time)
- Cp dec exponentially with time
- flow dependent elimination
Urine pH and drug elimination:
- Weak acids
- weak bases
-ionized species are trapped in urine and cleared quickly. Neutral forms can be reabsorbed
1.Weak acid- ex: phenobarbital, methotrexate, aspirin. Trapped in basic environments. Treat overdose with bicarbonate
RCOOH (lipid soluble) [RCOO- + H+] (trapped)
2.Weak bases- ex: amphetamines. Trapped in acidic environments. Treat overdose with ammonium chloride
RNH3 (trapped) [RNH2 + H+] (lipid soluble)
Drug metabolism
- Phase I
- Phase II
- Phase I
- reduction, oxidation, hydrolysis with cytochrome P-450 usually yield slightly polar water soluble metabolites (often still active)
- geriatric pts lose phase I first - Phase II
- conjugation (Glucuronidation, Acetylation, Sulfation) usually yields very polar, inactive metabolites (renally excreted)
- Geriatric pts have GAS (phase II). Pts who are slow acetylation have greater side effects from certain drugs because of the dec rate of metabolism
Efficacy vs. potency
- Efficacy -maximal effect a drug can produce. High efficacy drug classes are analgesic (pain) medications, antibiotics, antihistamines, decongestants. Partial agonists have less efficacy than full agonists
- potency- amount of drug needed for given effect. Inc potency, inc affinity for receptor. High potent drug classes include chemotherapeautic (cancer) drugs, antihypertensive (blood pressure) drugs, and antilipid (cholesterol) drugs
Receptor Binding:
- competitive antagonist
- Noncompetitive antagonist
- Partial agonist
- competitive antagonistshifts curve to rightdec potency, no change in efficacy. Can be overcome by increasing the concentration of agonist substrate. Ex: Diazepam + flumazenil on GABA receptor
- Noncompetitive antagonistshifts curve downdec efficacy. Cannot be overcome by increasing agonist substrate concentration. Ex: NE + phenooxybenzamine on alpha-receptors
- Partial agonist acts at same site as full agonist, but with reduced maximal effect dec efficacy. Potency is a different variable and can be inc or dec. Ex:morphine (full agonist) + buprenorphine (partial agonist) at opioid micro-receptor
Therapeutic index
- Measurement of drug safety
- LD50/ED50= median lethal dose/median effective dose
- TITLE: Therapeutuc Index= LD50/ED50
- safer drugs have higher TI values.
- ex: of drugs with low TI values include digoxin, lithium, theophylline, and warfarin
Therapeutic window
Meaure of clinical drug safety. Range of minimum effective dose to minimum toxic dose
Central & peripheral nervous system
1.para/sympathetic & somatic systems and their effects on organs system
1.parasympathtic:
-cardiac and smooth muscles,
-gland cells
Nerve terminals
- sympathetic
- sweat glands
- cardiac and smooth muscle
- gland cells
- nerve termainals
- renal vasculature
- smooth muscle - somatic
- skeletal muscle
- *note: that the adrenal meduall and asweat flands are part of the sympathetic nervous systentbut are innervated by cholinergic fibers
- botulinum toxix prevents release of neurotransmitter at all cholinergic terminals
ACh receptors
- Nicotinic ACh receptors are ligand-gated Na+/K+ channels; N(N) [found in automatic ganglia] and N(M) [found in neuromuscular junction) subtypes
- muscarinic ACh receptors are G-protein-coupled receptors that act through 2nd messengers
- 5 subtypes: M1, M2, M3, M4, M5
G-protein-linked 2nd messengers: sympathetic:
- receptors (4)
- G-protein class
- major functions
- alpha1–>q–>inc vascular smooth muscle contraction, inc pupillary dilator muscle contraction (mydriasis), inc intestinal and bladder sphincter muscle contraction
- alpha2–>i–>dec sympathetic outflow, dec insulin release dec lipolysis, inc platelet aggregation
- beta1–>s–>inc heart rate, inc contractility, inc renin release, inc lipolysis
- beta2–>s–>vasodialtion, bronchodilation, inc heart rate, inc contractility, inc lipolysis, inc insulin release, dec uterine tone (tocolysis), ciliary muscle relaxation, inc aqueous humor production
G-protein-linked 2nd messengers: parasymathetic
- receptors (3)
- G-protein class
- major functions
- M1–>q–>CNS, enteric nervous system
- M2–>i–>dec heart rate and contractility of atria
3.M3–>q–>inc exocrine gland secretion (eg. lacrimal, gastric acid), inc gut peristalsis, inc bladder contraction, bronchoconstriction, inc pupillary sphincter muscle contraction (miosis), ciliary muscle contraction (accommodation)
G-protein-linked 2nd messengers: Dopamine
- receptors (2)
- G-protein class
- major functions
- D1–>s–>relaxes renal vascular smooth muscle
2. D2–>i–>modulates transmitter release, especially in brain
G-protein-linked 2nd messengers: Histamine
- receptors (2)
- G-protein class
- major functions
- H1–>q–>inc nasal and bronchial mucus production, contraction of bronchioles, pruritus, pain
- H2–>s–>inc gastric acid secretion